The Australia-Israel Chamber of Commerce was delighted to host a boardroom lunch with Professor Andrew Cuthbertson AO, Non-Executive Director of CSL, and Senior Adviser to the CEO.

As you can imagine this was a very fascinating and timely discussion given CSL’s and Andrew’s pivotal role in the manufacture of Australia’s AstraZeneca COVID-19 vaccine supply.

Andrew gave us his insights into the challenges of developing a locally produced vaccine and the pathway forward for the vaccine.

Professor Andrew Cuthbertson AO is the Senior Advisor to the CEO (since 2020) of CSL Limited and an Executive Director (since 2018) on the CSL Limited board. Andrew served as the CSL R&D Director and Chief Scientific Officer since 1997.

He trained in Medicine and Science at the University of Melbourne gaining a MBBS and completed a PhD in Immunology at the Walter and Eliza Hall Institute in Australia.

He conducted molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He then worked at Genentech Inc. in San Francisco, in the team developing anti–VEGF therapy for age-related macular degeneration.

Andrew is on the Board for the Centre for Eye Research Australia (CERA), the Grattan Institute and the Council of the University of Melbourne.

Andrew is a Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and the Australian Academy of Technological Sciences.